Vice President, Johnson & Johnson Global External Innovation, Medical Devices
Bruce Rosengard is the Vice President for Medical Devices in Johnson & Johnson Global External Innovation (GEI). In this role, he sits on the GEI Leadership Team and is the global leader for all aspects of the GEI effort related to medical devices.
Bruce is an internationally recognized physician executive with notable achievements in the areas of clinical care delivery, basic and clinical research, medical education, public policy, device development, and organizational innovation within industry. He joined Johnson & Johnson Medical Devices in 2014, where he served as the Chief Medical Science and Technology Officer. In that role, he recruited a team of surgical scientists, who with partners in the Medical Device franchises executed 27 early-stage deals (2 onboarded) with J&J’s Innovation Centers and 19 equity investments (3 onboarded) with JJDC. Bruce conceived of, built, and launched the Center for Device Innovation in Houston. This unique collaboration between Johnson & Johnson and the Texas Medical Center provides front-end engineering capabilities for Medical Devices and a site for developing devices for cross-sector R&D initiatives, leveraging the largest medical complex in the world.
A cardiothoracic surgeon and NIH-funded immunologist, Bruce began his industry career at The Medicines Company, where he served as Vice President, New Business Ventures. He played a pivotal role in several major pharmaceutical acquisitions and was the architect of The Medicines Company’s Surgical and Perioperative Care franchise. Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the full-time faculty of Harvard Medical School. In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation immunology. Prior to this, Bruce was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered “beating heart” transplantation. Bruce started his academic career in the Departments of Surgery and Immunology at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure.
Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.